OrbiMed’s Regenxbio RGNX Stock Holding History

OrbiMed’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-267,700	Closed	-$8.67M	–	151
2020 Q1	$8.67M	Buy	267,700 +240,900	+899%	+$10M	0.15%	91
2019 Q4	$1.1M	Buy	+26,800	New	+$1.06M	0.02%	129

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OrbiMed's RGNX Position: Q2 2020 in Review

OrbiMed sold out of Regenxbio (RGNX) in Q2 2020, closing a stake of 267,700 shares — an estimated $8.67M sold.

OrbiMed first reported a position in RGNX in Q4 2019 and held it in 2 quarters. The position peaked at $8.67M in Q1 2020. 179 funds tracked by Wall St. Rank hold RGNX as of Q2 2020.

OrbiMed reported no remaining Regenxbio position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 267,700 Regenxbio shares in Q2 2020, an estimated $8.67M.
OrbiMed first reported a position in Regenxbio in Q4 2019 and held it in 2 quarters.
OrbiMed's Regenxbio position peaked at $8.67M in Q1 2020.
179 funds tracked by Wall St. Rank held Regenxbio as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.